Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD
Status:
Completed
Trial end date:
2015-11-10
Target enrollment:
Participant gender:
Summary
To provide additional, required information on the pharmacokinetic profile of SHP465 in the
targeted population (children and adolescents aged 6-17 years of age with ADHD).